



January 31, 2017

## **SCYNEXIS, Inc. to Participate in Upcoming Investor Conferences**

JERSEY CITY, N.J., Jan. 31, 2017 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX) today announced that the Company will participate in the following upcoming investor conferences:

- | Canaccord Genuity Rare Disease Conference at the InterContinental New York Barclay Hotel in New York City on Tuesday, February 7, 2017.
- | RBC Capital Markets Global Healthcare Conference at the Lotte New York Palace Hotel in New York City on Wednesday, February 22, 2017. The Company will present at 3:35 p.m. ET.

A live webcast of the RBC presentation will be available on the Investors section of the Company's website: [www.scynexis.com](http://www.scynexis.com). A replay of the presentation will be available approximately two hours after the event and will be available for two weeks following the presentation.

### **About SCYNEXIS**

SCYNEXIS is a pharmaceutical company committed to the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. We are developing our lead product candidate, SCY-078, as an oral and IV drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. For more information, visit [www.scynexis.com](http://www.scynexis.com).

#### CONTACT:

##### Media Relations

Blair McCarthy Atkinson

MacDougall Biomedical Communications

Tel: 781.235.3060

[batkinson@macbiocom.com](mailto:batkinson@macbiocom.com)

##### Investor Relations

Susan Kim

Argot Partners

Tel: 212-203-4433

[susan@argotpartners.com](mailto:susan@argotpartners.com)